Closed System Drug Transfer Devices Market By Type (Membrane-To-Membrane Systems, and Needleless Systems), By Design Type (Barrier Type, and Filtration Type), By End User (Hospitals, and Clinics),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028

Market Overview

The global Closed System Drug Transfer Devices market size is estimated at 1.94 billion USD with a CAGR of 20.7% during the forecasted period from 2021-2028. A Closed System Drug Transfer Devices is defined by the National Institute for Safety and Health as “a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.” CSTD are essential for healthcare workers since they prevent exposure of harmful drugs during drug transfer process. The key factor driving the Closed System Drug Transfer Devices market is attributed to increasing occurrence of cancer across the globe. Also, rising adoption of chemotherapy along with upsurge in approvals for chemotherapeutic drugs is positively influencing the market. Moreover, augmented danger of exposure to lethal drugs for healthcare workforces is projected to fuel this market. In addition, developing healthcare industry in emerging economies such as Asia Pacific is expected to boost the market size. Besides high-tech innovations along with improving regulatory rules is fostering this market. Moreover, increasing funding along with surge in research & development activities for closed system drug transfer device is considerably impacting the market size. On the other hand, lack of monitoring instructions concerning health workers safety along with deficient product efficacy in emerging economies may limit the market growth. Also, the current scenario of rising COVID-19 cases globally is projected to negatively affect the Closed System Drug Transfer Devices market owing to factors such as unstable economies, lockdowns issues, fear of visiting hospitals, shift of research activities towards coronavirus and so on.

Market Driver

Increasing prevalence of cancer is the prime factor boosting the global closed system drug transfer devices market. For instance, according to Cancer Research U.K., more than 360,000 new cancer cases are registered in the UK every year. The incidence rates for all cancers combined are projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035. In the U.K, there were around 183,000 new cancer cases in male and about 177,000 cancer cases in female, by 2015. Increase in prevalent cancer pool expands the diagnostic and treatment pool of cancer patients, thus demanding increased uptake of cancer treatments, including cytotoxic drugs, thereby boosting the demand for CSTDs.

Market Restraint

Lack of guidelines in emerging nations is one of the primary barrier hindering the entrenchment and high product demand for CSTDs in emerging nations. For instance, the healthcare statistics states that around 10 million healthcare personnel in China are exposed to hazardous drugs annually. In developing countries such as India, Brazil, Argentina, large volumes of health professionals are exposed to hazardous drugs. However, the usage rate of CSTDs is minimal in these nations due to non-compliance with safety standards. Developing nations hold a large untapped market potential for CSTDs,

Segment Analysis

Based on technology, the global Closed System Drug Transfer Devices market is broadly segmented as Membrane-To-Membrane Systems, and Needleless Systems. In 2018 Membrane-To-Membrane Systems is the dominant segment, and it accounts for approximately 50% of the market. Membrane-To-Membrane systems provide a double layer of protection for the safe transfer of hazardous drugs. It has a sealed expansion chamber that captures and retains hazardous drugs. Membrane-To-Membrane Systems has the largest share due to their ease of operation and the lower risk of contamination associated with double-membrane containment systems. Also, these systems use a double membrane junction between the syringe and the medication vial or container to help isolate medications. This double membrane containment system provides an added layer of protection compared to needleless membranes.

Regional Analysis

The global Closed System Drug Transfer Devices market is segmented into North America, Europe, South America, Asia Pacific, and ROW. North America is dominating the global Closed System Drug Transfer Devices market, due to the increasing incidence of cancer in the U.S. For instance, according to National Cancer Institute, in 2018, around 1,735,350 cases of cancer in the United States and 609,640 people are dead from the disease. The US is considered as a lucrative market for CSTDs due to high healthcare spending in this region. In 2016, total health care spending reached $3.4 trillion, increasing by 4.8% from 2015. By 2025, total healthcare care spending will account for 19.9% of GDP up from 17.8% in 2015, according to the CMS. Increased awareness of adverse effects due to hazardous drugs is created by healthcare agencies such as the National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA). CSTDs was first introduced to the US in 1998. The first approved CSTD was Phaseal. Currently, there are multiple CSTDs available in the US market. These include – Spiros, Texium with Smart Site, On Guard with Tevadaptor, ChemoClave, Equashield, ChemoLock, Vialshield, Halo and Arisure. The North America Closed System Drug Transfer Devices market size was XX million USD in 2018, and it will be 1376.70 million USD in 2025, with a CAGR 11.64% from 2019 to 2025. Europe is the second-largest market for Closed System Drug Transfer Devices in 2018, as the region has the presence of multiple government and non-government associations and organizations which focus on the awareness of safe handling of cytotoxic drugs such as European Agency for Safety and Health at Work (EU-OSHA), European Society of Oncology Pharmacy. For instance, In November 2015, the European Parliament (EP) formed a Commission to take action on chemical risk factors, including exposure to hazardous drugs. And in April 2016, the EP launched new policy recommendations on preventing occupational exposure to cytotoxic drugs as an initiative designed to protect healthcare professionals working across the EU.

Competitive Analysis

The major players include BD Medical, Inc, ICU Medical, Inc, Equashield, LLC, Corvida Medical, Teva Medical Ltd, Hospira, and others. The increasing launch of new Closed System Drug Transfer Devices is boosting the global Closed System Drug Transfer Devices market. For instance, October 9, 2018, ICU Medical, Inc., a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, have introduced the Diana ChemoLock Transfer Set for use with the Diana Compounding Workflow System has received United States Food and Drug Administration (FDA) 510K clearance. The Diana ChemoLock Transfer Set is a sterile, single-use closed system transfer device (CSTD) used to transfer drugs from a drug vial to an IV bag for intravenous drug administration. Moreover, in February 16, 2018, Baxter International Inc., a leader in innovative technology for medication delivery, have signed a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device, which consists of several components that work together to help prevent contaminants from entering the intravenous (IV) medication delivery system and the escape of hazardous substances out of the system during drug preparation and administration.

Global Closed System Drug Transfer Devices Market

• Consumption by Regions
  • North America
  • Europe
  • South America
  • Asia Pacific
  • ROW
• Segment by Type
  • Membrane-To-Membrane Systems
  • Needleless Systems
• Segment by Design Type
  • Barrier Type
  • Filtration Type
• Segment by End User
  • Hospitals
  • Clinics